Pharmaceutical laws in Nepal regulate how drugs are manufactured, registered, imported, exported, sold, distributed, and consumed across the country. The legal framework centers on the Drug Act 2035 (1978 A.D.) and a network of supporting regulations, policies, and institutional bodies designed to protect public health by ensuring drug safety, efficacy, and quality.
Nepal’s pharmaceutical sector has grown significantly since the establishment of the first domestic pharmaceutical industry (Chemi Drug) in 2026 B.S. Today the country has over 100 licensed manufacturers, 27,000+ pharmacies, and 5,000+ drug wholesalers — all operating within a regulatory environment that continues to evolve through legislative amendments and policy reforms.
Nepal’s pharmaceutical regulatory framework is built on multiple layers of legislation, regulations, and policy instruments. The table below summarizes the primary laws and their scope.
| Legislation / Policy | Year (B.S. / A.D.) | Scope |
|---|---|---|
| Drug Act 2035 | 2035 / 1978 | Primary law governing manufacture, sale, distribution, import, export, storage, and consumption of drugs |
| Narcotic Drugs (Control) Act 2033 | 2033 / 1976 | Control of narcotic and psychotropic substances; aligns with international conventions on controlled drugs |
| Drug Registration Regulation 2038 | 2038 / 1981 | Detailed procedures for drug registration, licensing, advertising, and clinical trial approvals |
| Drug Standard Regulation 2043 | 2043 / 1986 | Quality standards, testing protocols, and pharmacopoeial references for drugs |
| National Drug Policy 2052 | 2052 / 1995 | Policy framework for drug production, import, quality assurance, rational use, and information management |
| Nepal Pharmacy Council Act 2057 | 2057 / 2000 | Registration and regulation of pharmacy professionals; educational and ethical standards |
| Codes on Sale and Distribution of Drugs | 2041 / 1984 (revised 2071, 2080) | Standards for pharmacy and wholesale operations, storage, dispensing, and record-keeping |
| National GMP Code 2072 | 2072 / 2015 (amended 2079, 2082) | Good Manufacturing Practice standards for premises, equipment, production, quality control, and storage |
| Medicine Registration Guidance 2073 | 2073 / 2016 | Detailed guidance on drug registration procedures, documentation requirements, and bioequivalence |
| Vaccine Act 2072 | 2072 / 2016 | Administration and quality standards for vaccines; prequalification requirements |
The Drug Act 2035 is the cornerstone of pharmaceutical regulation in Nepal. Enacted on 2035/7/8 B.S. (25 October 1978), its stated purpose is to prevent the misuse or abuse of drugs, control false or misleading information about drug efficacy, and regulate drugs that are not safe, efficacious, or of standard quality.
The Drug Act has been amended four times to address evolving pharmaceutical and public health needs.
| Amendment | Year (B.S. / A.D.) | Key Changes |
|---|---|---|
| First Amendment | 2045 / 1988 | Expanded provisions on drug dispensing, hospital pharmacies, and professional qualifications |
| Second Amendment | 2057 / 2000 | Major expansion: drug categorization (Ka, Kha, Ga), prescription requirements, pharmacist definitions, enhanced penalties, compensation provisions, and ceiling on fines |
| Third Amendment | 2079 / 2022 | Emergency use authorization for drugs and vaccines (Section 9A); mandatory DDA approval before clinical trials of new drugs or vaccines |
| Fourth Amendment | 2082 / 2025 | Further modernization of regulatory provisions aligned with global standards |
The Drug Act defines “drug” broadly as any substance used for diagnosis, cure, mitigation, treatment, or prevention of disease in humans, animals, or birds, or any substance used to affect the structure or physiological function of the body, including allied ingredients and components.
| Term | Definition Under Drug Act 2035 |
|---|---|
| Drug | Any substance for diagnosis, cure, mitigation, treatment, or prevention of disease; includes substances affecting body structure or function, and allied ingredients |
| Pharmacist | A person who has graduated in pharmacy or pharmaceutics and been recognized by the Drugs Advisory Committee |
| Pharmacy Assistant | A person who has passed certificate level or equivalent in pharmacy and been recognized by the Drugs Advisory Committee |
| Consumption | Administering a drug by a doctor, authorized person, or patient to improve physical or mental condition according to prescription |
| Department | The Department of Drug Administration (DDA) constituted under the Act |
The Department of Drug Administration is the national regulatory authority for pharmaceuticals in Nepal. Established in 2036 B.S. (1979 A.D.) under the Drug Act, the DDA operates under the Ministry of Health and Population with its headquarters in Bijulibazar, New Baneshwor, Kathmandu, and branch offices in Biratnagar, Birgunj, and Nepalgunj.
| Division / Section | Key Functions |
|---|---|
| Registration Division (Domestic) | Issue recommendation letters for pharmaceutical industry establishment; issue product manufacturing licenses; approve plant layouts; evaluate new products and grant marketing permission |
| Registration Division (Import & Export) | Register foreign manufacturers and products; issue import/export recommendation letters and renewals; manage raw material import permits |
| Inspection Division | Inspect drug industries, wholesale and retail pharmacies; take enforcement action for Drug Act non-compliance; coordinate WHO-GMP audits |
| Drug Management Section | Register and certify retail/wholesale pharmacy outlets; issue and renew sale-distribution certificates; regulate narcotic and psychotropic drug sales |
| Quality Assurance Section | Coordinate with the National Medicine Laboratory for drug testing; manage pharmacovigilance and adverse drug reaction monitoring |
| Administration Section | Annual planning; coordination with MoHP, departments, and NGOs; monthly, quarterly, and yearly reporting; monitoring of regional offices |
| Legal Section | Prepare documents for court cases against non-compliant pharmacies and industries; provide legal counsel to the department |
Under Section 6 of the Drug Act, the Drug Research Laboratory (now the National Medicine Laboratory) is the principal government body for scientific research, testing, and analysis of drugs. Any domestic or foreign person or institution seeking to establish a research center or laboratory for drug research must obtain Government of Nepal approval.
The Drug Act establishes two advisory bodies that play critical roles in pharmaceutical policy and regulation.
| Body | Established | Role |
|---|---|---|
| Drugs Advisory Council | 2037 B.S. (1980) | High-level policy advisory body; advises the government on drug-related matters including legislative reforms and national drug policy |
| Drugs Advisory Committee | 2037 B.S. (1980) | Technical advisory body; recommends drug registration approvals, emergency use authorizations, recognition of professional qualifications, and classification of drug categories |
Establishing a pharmaceutical manufacturing industry in Nepal requires a multi-step licensing process through the DDA, governed by Chapter 4 (Sections 7–11) of the Drug Act and the Drug Registration Regulation 2038.
| Step | Requirement | Details |
|---|---|---|
| 1. Recommendation letter | Section 7, Drug Act | Apply to DDA with a feasibility study report and prescribed documents (Schedule 1 & 2 of Drug Registration Regulation). DDA evaluates and issues the recommendation letter for industry establishment. |
| 2. Plant layout approval | DDA Registration Division | Submit pharmaceutical manufacturing plant layout for DDA inspection and approval before construction. |
| 3. Product manufacturing license | Section 8, Drug Act | After obtaining the recommendation letter, apply for a product license from DDA before commencing manufacturing. License fee: NPR 200 (initial), NPR 50 (renewal). |
| 4. Drug registration | Section 9, Drug Act | Each drug product must be registered with DDA and a drug registration certificate obtained before sale or distribution. Requires specifications in DMF format, analytical reports from accredited labs, and bioavailability/bioequivalence data where applicable. |
| 5. WHO-GMP certification | National GMP Code 2072 | Manufacturing facilities must comply with WHO Good Manufacturing Practice standards. DDA conducts GMP audits and issues certification. GMP status affects eligibility for new product licenses and market licenses. |
| 6. License renewal | Section 11, Drug Act | All licenses and certificates are valid for two years. Renewal must be completed within 35 days of expiry by paying prescribed fees. |
Importing or exporting pharmaceutical products in Nepal requires specific authorization from the DDA under Sections 10 and 11 of the Drug Act.
| Process | Requirements |
|---|---|
| Import of finished drugs | Foreign manufacturer must be registered with DDA; each drug product must hold a valid drug registration certificate; importer must obtain a recommendation letter from DDA before securing an import license |
| Import of raw materials | Licensed domestic manufacturers may import raw materials with a DDA recommendation letter; letter must be renewed periodically |
| Export of drugs | Manufacturer must hold valid product license and GMP certification; recommendation letter required from DDA before obtaining export license |
| Narcotic and psychotropic imports | Special DDA recommendation required; coordinated with the International Narcotic Control Board (INCB) under the Narcotic Drugs (Control) Act 2033 |
Any person or entity selling or distributing drugs in Nepal must register with the DDA and obtain the appropriate certificate. The Codes on Sale and Distribution of Drugs (first published 2041 B.S., revised 2071 and 2080 B.S.) set the detailed operational standards.
| Certificate Type | Requirement | Key Conditions |
|---|---|---|
| Retail pharmacy certificate | Registration with DDA | Must employ a registered pharmacist with valid Nepal Pharmacy Council license present during all operating hours; proper storage conditions required; maintain purchase and sale records |
| Wholesale certificate | Registration with DDA | Compliance with Good Storage and Distribution Practices (GSDP) guidelines; temperature and humidity monitoring; batch traceability records |
| Vyabashahi certificate | DDA authorization | For persons authorized to sell medicines without a pharmacy degree; limited to specific drug categories |
Only registered entities with valid certificates may legally sell and distribute drugs. Certificates are valid for a specified period and must be renewed. There are over 27,000 pharmacies and 5,000 wholesalers operating under this framework across Nepal.
The Second Amendment to the Drug Act introduced a drug categorization system under Section 17 that determines how drugs may be sold and who may prescribe them.
| Category | Description | Sale Requirement |
|---|---|---|
| Category Ka (क) | Drugs that can only be sold on a doctor’s prescription | Prescription from a registered medical practitioner is mandatory |
| Category Kha (ख) | Drugs that can be sold by a pharmacist or pharmacy assistant without prescription | Must be sold by or under the supervision of a qualified pharmacist or pharmacy assistant |
| Category Ga (ग) | Over-the-counter drugs | Can be sold without prescription, but must comply with labeling and quality requirements |
The provisions relating to prescriptions are governed by Section 27 of the Drug Act. Recognized doctors, integrated (traditional) doctors, and health workers authorized under the Act may issue prescriptions for categorized drugs.
Nepal’s pharmaceutical quality framework is enforced through multiple mechanisms including GMP compliance, laboratory testing, pharmacovigilance, and market surveillance.
The National GMP Code sets minimum manufacturing standards covering premises, equipment, personnel, documentation, production processes, quality control, and storage. It has been amended twice — in 2079 B.S. (ministerial level) and 2082 B.S. (ministerial level) — reflecting Nepal’s alignment with global manufacturing norms. Deurali Janta Pharmaceutical was Nepal’s first WHO-GMP certified pharmaceutical industry.
| Provision | Section | Requirement |
|---|---|---|
| Quality standard requirement | Section 12 | All drugs must be safe for public consumption, efficacious, and of quality standard. Manufacturing, selling, or distributing substandard drugs is prohibited. |
| Product recall | Section 14 | If a marketed drug is found unsafe or substandard, the manufacturer or agent must retrieve it from sellers and distributors. The DDA Administrator may order recall. |
| Compensation | Section 15 | If a substandard drug causes death or injury, the manufacturer must compensate the affected person. Liability attaches to the manufacturer regardless of intermediary distribution. |
| Labeling | Section 13 | Drug labels must clearly indicate potential side effects, expiration date, batch number, and other prescribed information. |
| Pharmacovigilance | DDA directive | Nepal joined the WHO Pharmacovigilance Programme in 2006. Currently 20 regional pharmacovigilance centers operate across the country for adverse drug reaction monitoring. |
The Third Amendment (2079 B.S.) introduced Section 9(A), which authorizes the DDA to register a drug or vaccine for emergency use in Nepal to prevent, control, or mitigate communicable diseases leading to an epidemic. This provision, prompted by the COVID-19 pandemic, requires the drug or vaccine to be listed with the WHO or approved for emergency use by a recognized foreign regulatory authority. The DDA may cancel the registration if the drug causes adverse effects or if WHO or the originating country revokes its approval.
The Drug Act empowers inspectors to enforce compliance across the pharmaceutical supply chain. Inspectors appointed under the Act have broad authority to enter, inspect, and investigate any premises involved in drug manufacturing, storage, or distribution.
| Inspection Power | Details |
|---|---|
| Entry and inspection | Inspectors may inquire, inspect, and search any location involved in drug manufacturing, storage, or distribution |
| Sealing and cessation | If a drug is suspected unsafe, inefficacious, or substandard, the inspector may seal the drug, withhold it, and order cessation of activities |
| Reporting | Inspector must submit a report to the DDA Administrator within three days of any inspection or enforcement action |
| Seizure and destruction | The Administrator may order seizure or destruction of unsafe drugs and cancel related licenses or certificates |
| Price fixing | Under Section 26, DDA may fix the price of any drug with government approval, published via Nepal Gazette notification |
The Drug Act establishes clear prohibitions and corresponding penalties for violations. Penalties were significantly strengthened by the Second Amendment.
| Offense | Section | Penalty |
|---|---|---|
| Manufacturing or selling without license | Section 28, 34 | Imprisonment up to 3 years and/or fine. Manufacturing, selling, distributing, dispensing, storing, exporting, or importing drugs without adequate human resources and materials is prohibited. |
| Drug adulteration | Section 29, 34 | Imprisonment up to 3 years and/or fine. Adulterating any drug or selling adulterated drugs is a criminal offense. |
| Selling expired drugs | Section 30, 34 | Imprisonment up to 3 years and/or fine for selling drugs past their expiration date. |
| Misuse or abuse of drugs | Section 20 | No person shall misuse or abuse drugs. Selling drugs in contravention of categorization rules constitutes misuse. |
| False advertising | Section 21 | False or misleading information about a drug’s efficacy or use is strictly prohibited. Advertising requires DDA licensing. |
| Selling non-drug as drug | Section 32 | Selling any other substance representing it to be a drug is punishable. |
| Unauthorized clinical trials | Section 33 | Conducting clinical trials of new drugs or vaccines without DDA approval is prohibited (strengthened by Third Amendment). |
| Fine ceiling | Section 35 | Fine shall not exceed the amount in controversy (Bigo) or NPR 100,000, whichever is higher. Imprisonment in lieu of fine shall not exceed 5 years. |
The Nepal Pharmacy Council (NPC) was established under the Nepal Pharmacy Council Act 2057 (2000 A.D.) and became operational in 2059 B.S. (2002 A.D.). It regulates the pharmacy profession by enforcing educational, ethical, and professional standards.
| Function | Details |
|---|---|
| Professional registration | All pharmacists and pharmacy assistants must register with NPC and obtain a valid practicing license |
| Licensing examination | Conducts name registration examinations for pharmacy graduates (first exam held 2071/6/4 B.S.) |
| Educational recognition | Gives recognition to educational institutes teaching pharmacy and certificates granted by such institutes |
| Policy development | Prepares policies, plans, and programs for systematic operation of pharmacy business in Nepal |
| Annual license renewal | Pharmacists must renew their practicing license annually with NPC |
Separate from the Drug Act, the Narcotic Drugs (Control) Act 2033 (1976 A.D.) specifically addresses controlled substances. This legislation aligns Nepal’s drug control policies with international conventions on narcotic and psychotropic substances and regulates the lawful production, distribution, and use of controlled substances while implementing strict measures to prevent illicit drug trafficking and abuse. Import of narcotic and psychotropic substances requires special DDA recommendation coordinated with the International Narcotic Control Board (INCB).
The National Drug Policy 2052 (1995 A.D.) provides the overarching policy framework for Nepal’s pharmaceutical sector. Developed in accordance with the National Health Policy 1991, it covers drug production, import, export, storage, supply, sales, distribution, quality assessment, regulatory control, rational use, and information management. The policy coordinates government, non-government, and private organizations involved in pharmaceutical activities and supports the strategic objectives of the DDA.
Nepal maintains an Essential Drug List (EDL) first published in 1986 A.D. and revised six times, with the latest revision in 2021 containing 398 medicines. The EDL serves as the basis for public procurement, insurance coverage, and prescribing guidelines, and the government provides 98 types of medicines free of cost through the public health system. The government has also fixed prices for 96 types of medicines to ensure affordability.
Establishing a pharmaceutical business in Nepal requires compliance with both the pharmaceutical regulatory framework and general business registration requirements. Entrepreneurs must register their business entity under the Company Act 2063 or with the local Ward Office, in addition to obtaining all DDA-specific licenses. For guidance on general business formation, see our guide on startup registration in Nepal. Pharmaceutical businesses must also comply with labor law requirements, income tax obligations, and contract enforcement standards applicable to all businesses operating in Nepal.
Pharmaceutical disputes in Nepal are adjudicated through the court system. Violations of the Drug Act may result in criminal prosecution in the District Courts, with appeals progressing to the High Courts and ultimately the Supreme Court of Nepal.
| Legal Remedy | Details |
|---|---|
| Criminal prosecution | DDA’s Legal Section prepares documents and registers cases in court against non-compliant pharmacies and industries |
| Administrative action | DDA Administrator may cancel licenses, order product recalls, and impose operational cessation orders |
| Complaint to MoHP | Under Section 25, a person dissatisfied with the Administrator’s decision may file a complaint with the Ministry of Health within 35 days |
| Compensation claims | Individuals harmed by substandard drugs may claim compensation from the manufacturer under Section 15 |
| Development | Year | Significance |
|---|---|---|
| Emergency Use Authorization | 2079 B.S. | Third Amendment introduced Section 9(A) allowing DDA to register drugs and vaccines for emergency use during epidemics |
| Good Pharmacy Practices (GPP) | 2080 B.S. | Nepal’s first GPP guidelines developed with USAID MTaPS support, setting service quality standards for 27,000+ pharmacies |
| Good Storage and Distribution Practices (GSDP) | 2080 B.S. | First national GSDP guidelines for 5,000+ drug wholesalers, ensuring product quality throughout the supply chain |
| Revised Codes on Sale and Distribution | 2080 B.S. | Updated CSD replacing the 2071 version, addressing gaps in pharmacy and wholesale practice standards |
| GMP Code amendments | 2079 & 2082 B.S. | Two amendments to the National GMP Code 2072 strengthening manufacturing practice requirements |
| Fourth Amendment to Drug Act | 2082 B.S. | Latest amendment further modernizing pharmaceutical regulatory provisions |
| Electronic regulatory system | Ongoing | DDA working with USAID MTaPS to develop an integrated electronic regulatory information system for marketing authorization, surveillance, licensing, and inspection |
Nepal’s pharmaceutical regulatory framework, anchored by the Drug Act 2035 and enforced by the Department of Drug Administration, provides comprehensive governance over drug manufacturing, registration, import, export, sale, distribution, and quality assurance. The system has matured significantly through four legislative amendments, the establishment of the Nepal Pharmacy Council, adoption of GMP standards, and recent introduction of emergency use authorization and good practice guidelines. For pharmaceutical businesses, manufacturers, importers, pharmacists, and healthcare providers operating in Nepal, understanding and complying with these laws is not just a legal obligation but essential for public health protection and sustainable business operation. For questions about regulatory compliance, contract enforcement, or any aspect of Nepal’s legal framework, professional legal counsel is strongly recommended.
The Drug Act 2035 (1978 A.D.) is the primary legislation governing pharmaceuticals in Nepal. It regulates the manufacture, sale, distribution, import, export, storage, and consumption of drugs and establishes the Department of Drug Administration (DDA) as the national regulatory authority under the Ministry of Health and Population.
The DDA is Nepal's national regulatory authority for pharmaceuticals, established in 2036 B.S. (1979 A.D.) under the Drug Act. Headquartered in Bijulibazar, Kathmandu, with branch offices in Biratnagar, Birgunj, and Nepalgunj, it oversees drug registration, licensing, quality control, inspection, pharmacovigilance, and enforcement of pharmaceutical laws.
The Drug Act has been amended four times: the First Amendment in 2045 B.S. (1988), Second Amendment in 2057 B.S. (2000), Third Amendment in 2079 B.S. (2022), and Fourth Amendment in 2082 B.S. (2025). Key changes include drug categorization, emergency use authorization for vaccines and drugs, and mandatory DDA approval for clinical trials.
Establishing a drug manufacturing industry requires: (1) obtaining a recommendation letter from DDA, (2) getting plant layout approval, (3) acquiring a product manufacturing license, (4) registering each drug product with DDA, (5) achieving WHO-GMP certification, and (6) renewing licenses every two years within 35 days of expiry.
Nepal classifies drugs into three categories under Section 17 of the Drug Act: Category Ka (क) requires a doctor's prescription; Category Kha (ख) can be sold by a pharmacist or pharmacy assistant without prescription; and Category Ga (ग) are over-the-counter drugs that can be sold without prescription.
Violations including manufacturing without a license, drug adulteration, selling expired drugs, and false advertising carry penalties of imprisonment up to 3 years and/or fines. The fine ceiling is the amount in controversy or NPR 100,000, whichever is higher. Imprisonment in lieu of unpaid fines cannot exceed 5 years.
Yes. Every retail pharmacy in Nepal must employ a registered pharmacist holding a valid practicing license from the Nepal Pharmacy Council. The pharmacist must be present during all operating hours and is responsible for medicine dispensing and pharmaceutical services. Non-pharmacists may own pharmacies but must employ a licensed pharmacist.
The Nepal Pharmacy Council (NPC) was established under the Nepal Pharmacy Council Act 2057 (2000 A.D.) to regulate the pharmacy profession. It registers pharmacists and pharmacy assistants, conducts licensing examinations, recognizes educational institutions, and enforces ethical and professional standards across the pharmacy sector.
Importing drugs requires: (1) the foreign manufacturer must be registered with DDA, (2) each drug product must have a valid drug registration certificate, and (3) the importer must obtain a DDA recommendation letter before securing an import license. Narcotic and psychotropic substances require special authorization coordinated with the International Narcotic Control Board.
Introduced by the Third Amendment (2079 B.S.) through Section 9(A), emergency use authorization allows DDA to register a drug or vaccine for use during epidemics at the recommendation of the Drugs Advisory Committee. The product must be WHO-listed or approved for emergency use by a recognized foreign regulatory authority. DDA may cancel the registration if adverse effects emerge.
The National GMP Code 2072 (2015 A.D.) sets minimum Good Manufacturing Practice standards for pharmaceutical production in Nepal, covering premises, equipment, personnel, documentation, production processes, quality control, and storage. It has been amended in 2079 and 2082 B.S. to align with global manufacturing norms. DDA conducts GMP audits and certification.
Nepal's Essential Drug List (EDL), first published in 1986 and revised six times (latest 2021), contains 398 medicines. It serves as the basis for public procurement, insurance coverage, and prescribing guidelines. The government provides 98 medicines free of cost through the public health system and has fixed prices for 96 types of medicines.
At Nepal Divorce Services, Nepal's first specialized divorce law firm, we understand that taking the first step toward divorce can feel overwhelming. Our experienced divorce lawyers are here to guide you through the legal process and help you move forward with confidence and clarity.
Whether you're inside or outside Nepal and need assistance with filing a divorce case, our services are accessible worldwide. Contact us at +977 9841114443, on WhatsApp, or Viber.
